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Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms Huib A M Kerstjens, Paul L P Brand, Petra M de Jong, Gerard H Koeter, Dirkje S Postma, and the Dutch CNSLD Study Group Abstract Background -Despite effective treatments, the morbidity and mortality of obstructive airways disease (asthma and COPD) remains high. Home monitoring of peak expiratory flow (PEF) is increasingly being advocated as an aid to better management of obstructive airways disease. The few available studies describing effects of treatment on the level and variation of PEF have involved relatively small numbers of subjects and did not use control groups. Methods -Patients aged 18-60 years were selected with PC20 < 8 mglml and FEV, <95% confidence interval ofpredicted normal. They were randomised to receive, in addition to a P2 agonist, either an inhaled corticosteroid (BA + CS), an anticholinergic (BA + AC), or a placebo (BA + PL). One hundred and forty one of these subjects with moderately severe obstructive airways disease completed seven periods of two weeks of morning and afternoon PEF measurements at home during 18 months of blind follow up. Results -Improvements in PEF occurred within the first three months of treatment with BA + CS and was subsequently maintained: the mean (SE) increase in morning PEF was 51 (8) /min in the BA + CS group compared with no change in the other two groups. Similarly, afternoon PEF increased by 22 (7) 1min. Diurnal variation in PEF (amplitude %/omean) decreased from 18*0% to 10-2% in the first three months of treatment with BA + CS. Within-subject relations between changes in diurnal variation in PEF and changes in PC20 were found to be predominandy negative (median p -0 40) but with a large scatter. Relations between diurnal variation in PEF and changes in symptom scores, FEV1, and bronchodilator response were even weaker. Conclusions -In patients with moderately severe obstructive airways disease, PEF rates and variation are greatly improved by inhaled corticosteroids. Since the relation of diurnal PEF variation with PC20, symptoms, FEV1, and bronchodilator response were all weak, these markers of disease severity may all provide different information on the actual disease state.
PEF measurements should be used in addition to the other markers but not instead of them. (Thorax 1994; 49:1109 -1115 Peak expiratory flow (PEF) measurements are increasingly recommended to aid in the diagnosis and management of asthma."1 The National Asthma Education Program, for instance, has recently stated that PEF measurements are a valuable clinical tool for assessing the degree of airflow obstruction and monitoring the response to therapy.7 To date, however, the effect of different treatments on level of PEF -and especially on PEF variation -has not been extensively documented. An improvement in PEF with inhaled corticosteroids, for instance, has been shown only in two relatively small controlled studies.89 In a recent long term study ofmild, newly detected adult asthmatic patients, Haahtela and colleagues compared the results of treatment with budesonide and terbutaline and showed improvements in both morning and evening PEF with budesonide. The effects of treatment on diurnal variation in PEF were not presented.'
To our knowledge, a decrease in diurnal variation in PEF with inhaled corticosteroids has been documented only in children.'01'
The variation in PEF is thought by many to reflect the degree of airway hyperresponsiveness.7 It is important to note, however, that most of the epidemiological'2-" and clinical'5"'" studies are cross sectional, whereas longitudinal, within-subject relations between PC20 and PEF variation (and symptom scores) are more relevant. This is especially pertinent for self-management plans which rely on home measurements of PEF. Only one report has documented this within-subject relation between diurnal PEF variation and PC20: a weak relationship was found in a small cohort study ofasthmatic patients not receiving standardised therapy. 8 We have recently completed a double blind, controlled, multicentre clinical trial in patients with obstructive airways disease and a broad range of patient characteristics. "9 In the current report the influence of treatment with inhaled corticosteroids and/or bronchodilators on morning and afternoon PEF levels, as well as on diurnal variation in PEF, is tested. Subsequently, the interrelationships between diurnal PEF variation, PC20, and symptoms are Kerstiens, Brand, de _'ong, Koeter, Postma described, both cross sectionally between subjects, and longitudinally within subjects.
Methods
Patients aged 18-60 years with respiratory symptoms and no other major illnesses20 were selected according to the following criteria: (1) FEV, ranging between 4-5 and 1 64 residual standard deviations (RSD) below the predicted value -that is, between 2-30 and 0-84 litres below predicted normal FEV, for men or between 1-71 and 0-62 litres below predicted for women -or FEV1/IVC (inspiratory vital capacity) more than 1-64 RSD (men: 11-76%, women: 10-68%) below the predicted value, provided that total lung capacity was normal (higher than 1 64 RSD (men: 1.15, women: 0-98 litres) below the predicted level2"). FEV, had to be larger than 1-2 litres; and (2) 20 Patients were asked to keep PEF records and a diary card for 14 consecutive days before each visit. After standardised instruction in the outpatient clinic, patients used a Wright mini peak flow meter (Clement Clarke International Ltd, London, UK) to record PEF values at home. The best of three blows was recorded in the morning (directly after rising, before bronchodilator therapy) and in the afternoon (before the evening meal, before bronchodilator therapy). PEF values were recorded on a separate sheet in the diary. Symptom scores were noted on a four-point scale (0= no symptoms, 3=severe symptoms) daily for wheeze, dyspnoea, cough, and phlegm, separately.
Using data from a standardised history, different syndromes were identified which adhered to the criteria of the American Thoracic Society. 22 Patients reporting attacks of breathlessness and wheeze (asthmatic attacks) without chronic (that is, for more than three months per year) cough and sputum production were identified as having asthma. Current or former smokers without a history of asthmatic attacks, reporting either chronic cough with or without sputum production or dyspnoea when walking quietly on level ground, or both, were included in the chronic obstructive pulmonary disease group (COPD). Patients with both asthmatic attacks or recurrent wheeze and chronic cough and sputum production were labelled asthmatic bronchitics. Subjects with insufficient data to establish a diagnosis from history taking were included in an undefined diagnosis group.20 DATA 
ANALYSIS
PEF records and symptom scores on the diary cards were accepted only if at least nine of 14 days were filled in completely. Of the 274 patients who entered the study, 222 provided acceptable PEF records at the baseline visit and 235 acceptable diary cards. As the objectives of the current analyses were focused on time and treatment effects on PEF, the analyses are limited to those patients with acceptable baseline PEF and diary cards (n = 204) and to patients who also had at least 18 months of follow up (n = 141). These patients had a slightly higher PEF value in 1/min (as measured from flowvolume curves) at the baseline visit than the patients excluded from the current analyses ( Calculations with PC20 were performed using the base 2 logarithm as this reflects doubling doses and normalised the distribution. For the purposes of analysis, patients already responding to saline or to the lowest concentration of histamine (0 03 mg/ml) were assigned a PC20 vaiue of 0-015, being half the lowest concentration applied.20 The Twenty three of the 62 patients (37%) on BA+CS had a diurnal PEF variation greater than 20% at the baseline visit; after three months of treatment this proportion dropped to 14% (X2 test, p<0001) to remain approximately constant at further follow up visits. There were no significant changes in the proportions of patients having a diurnal variation in PEF greater than 20% in the other two treatment arms.
BETWEEN-SUBJECT RELATION OF DIURNAL VARIATION IN PEF TO OTHER MARKERS OF DISEASE SEVERITY
The cross sectional correlation between diurnal variation in PEF and log2PC20 at the baseline visit (p= -0 39, p<0 001) became somewhat stronger at later visits (p-0.50, -0-60, and -0-59 after six, 12, and 18 months, respectively), but a large scatter persisted ( fig  2) ; the relation was comparable in the three treatment arms (BA + CS; p = -0-48, BA+AC: p=-0 54, and BA+PL: p=-048 after 18 months of treatment).
Changes in diurnal variation in PEF from the baseline to the first follow up visit were negatively related to changes in PC20 (p= -031, p<0001, table 2), largely due to changes in the BA + CS group. Similarly, changes in diurnal variation in PEF were negatively related to changes in FEV,%pred (p = -0-31, p<005). There was no relation between changes in diurnal variation in PEF and changes in symptom scores (table 2) .
For the BA+CS group, the temporal relationships of changes in diurnal variation in PEF, PC20, and symptom scores are shown in 
WITHIN-SUBJECT RELATION OF DIURNAL VARIATION IN PEF WITH OTHER MARKERS OF DISEASE SEVERITY
To determine the strength of the association between diurnal variation in PEF and PC20 within patients, individual rank correlation coefficients were calculated (table 3) . Although a predominantly negative association was found (median p-0 40), the scatter was rather large (90% range -1-00 to 0-80, fig 4A) . Within patients there was also a significant, though weak, relation between changes in diurnal variation in PEF and changes in symptom scores ( fig 4B) . The relations between diurnal variation in PEF and the other markers of disease severity were similar between the different treatment and diagnostic groups (table 3) . ease. Simultaneously, diurnal variation in PEF decreased. These improvements occurred within the first three months of treatment and were subsequently maintained. Because diurnal variation in PEF is reduced with inhaled corticosteroids, physicians classifying patients as (non)asthmatic on the basis of a certain degree of PEF variation'7 should take into account prior treatment with corticosteroids. The improvement in PEF levels and variation with inhaled corticosteroids was paralleled by an improvement in FEVy19 and by an improvement in symptom scores. By contrast, although the greatest improvement in PC20 occurred within the first six months, the improvement continued until at least one year (fig 3) . This is an important finding as airway hyperresponsiveness continued to improve even when changes in PEF and FEV, could no longer be demonstrated. The longitudinal relation between variation in PEF and PC,0 cannot therefore be as close as is suggested from some cross sectional analyses,'625 although not from others.'4'826 More important than these between-subject analyses, however, is the weakness of the within-subject correlations between changes in PEF variation and other markers of disease severity such as symptoms, FEVI, and PC20. Our results in a large group of patients on standardised treatment confirm and extend the observations ofJosephs et al in an open and uncontrolled follow up study of eight children and 12 adults with mild asthma.'8 Although in our study the relation between diurnal variation in PEF and PC20 was stronger (median p = -0 40) than between PEF variation and either FEV,, bronchodilator response, or symptom scores (median p-0-23, 0 20, and 0-25 respectively), considerable scatter existed for all four measurements (table 3, fig 4A,B) . This implies that PEF variation and the other three markers of disease severity (PC2O, FEVI, symptom scores) are not interchangeable and perhaps provide different information on the actual state and are informative in their own right.
The within-subject relation between diurnal variation in PEF and PC20 was not significantly different between patients with a symptom based diagnosis ofasthma, asthmatic bronchitis, or chronic obstructive pulmonary disease (COPD) (table 3). Although a high variation in PEF is considered characteristic of asthma,45 considerable variation in PEF has been found to be present in many current or former smokers without asthmatic attacks.'526 Our study group was selected on the basis of objective criteria of age, FEV, and PC20. Increased responsiveness to methacholine has recently been shown to be present in more than two thirds of patients with early COPD.27 In our population a large overlap was found, not only in PC20, but also in PEF variation between patients with a symptom based diagnosis of asthma and COPD.26 Both PEF levels and PC20 are also unimodally distributed in the general population.'228 Reliable separation of patients 
